FDA approves first pill to prevent recurrent C. difficile infections 

The Food and Drug Administration approved the first fecal microbiota product taken orally to prevent recurrent C. difficile infection. 

“Today’s approval provides patients and healthcare providers a new way to help prevent recurrent C. difficile infection,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “The availability of a fecal microbiota product that can be taken orally is a significant step forward in advancing patient care and accessibility for individuals who have experienced this disease that can be potentially life-threatening.”